Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about MIRA Pharmaceuticals, Inc.
MIRA Pharmaceuticals, Inc. News
May 28, 2025 - accessnewswire.com
MIRA Pharmaceuticals to Participate in BIO 2025 in Boston and Highlights Ongoing Progress Across Clinical Program
May 8, 2025 - accessnewswire.com
MIRA Pharmaceuticals Announces Board Approval of SKNY Acquisition Reflecting $60+ Million in Combined Enterprise Value Based on Independent Review
May 6, 2025 - accessnewswire.com
MIRA Pharmaceuticals Reports No Brain Toxicity in FDA-Required Study of Ketamir-2, Confirming Absence of Ketamine-Linked Neurotoxicity
Apr 23, 2025 - accessnewswire.com
MIRA Pharmaceuticals Reports Positive In Vitro Drug Release Data for Topical Ketamir-2, Targeting $11B+ U.S. Topical Pain Relief Market and Exploring FDA Fast Track Designation
MIRA Pharmaceuticals, Inc. Quantitative Score
About MIRA Pharmaceuticals, Inc.
MIRA Pharmaceuticals, Inc. operates as a clinical development stage biopharmaceutical company. The company focuses on the development and commercialization of a new molecular synthetic tetrahydrocannabinol (THC) analog under investigation for the treatment of adult patients with anxiety and cognitive decline typically associated with early-stage dementia. It is developing MIRA1a, a synthetic cannabinoid analog to treat anxiety and chronic pain by targeting the cannabinoid type 1 and type 2 receptors. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Baltimore, Maryland.
MIRA Pharmaceuticals, Inc. Earnings & Revenue
What’s This Company Really Worth? Find Out Instantly.
Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.
MIRA Pharmaceuticals, Inc. Financials
Table Compare
Compare MIRA metrics with: | |||
|---|---|---|---|
Earnings & Growth | MIRA | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | MIRA | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | MIRA | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | MIRA | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
MIRA Pharmaceuticals, Inc. Income
MIRA Pharmaceuticals, Inc. Balance Sheet
MIRA Pharmaceuticals, Inc. Cash Flow
MIRA Pharmaceuticals, Inc. Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Neutral |
| Return on Equity | Strong Sell |
| Return on Assets | Strong Sell |
| Debt/Equity Ratio | Strong Sell |
| Price/Earnings Ratio | Strong Sell |
| Price/Book Ratio | Strong Sell |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Historical Market Cap
Shares Outstanding
MIRA Pharmaceuticals, Inc. Executives
| Name | Role |
|---|---|
| Mr. Erez Aminov | Chief Executive Officer & Chairman |
| Ms. Michelle Yanez M.B.A. | Chief Financial Officer, Secretary & Treasurer |
| Dr. Itzchak Angel Ph.D. | Chief Scientific Advisor |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Mr. Erez Aminov | Chief Executive Officer & Chairman | Male | 1979 | 626.19K |
| Ms. Michelle Yanez M.B.A. | Chief Financial Officer, Secretary & Treasurer | Female | 1973 | 185.12K |
| Dr. Itzchak Angel Ph.D. | Chief Scientific Advisor | -- |
MIRA Pharmaceuticals, Inc. Insider Trades
| Date | 9 Dec |
| Name | Whalen Matthew Pratt |
| Role | Director |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 25000 |
| Date | 9 Dec |
| Name | MacPherson Edward Clouston |
| Role | Director |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 25000 |
| Date | 9 Dec |
| Name | Yanez Michelle |
| Role | Chief Financial Officer |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 150000 |
| Date | 9 Dec |
| Name | Aminov Erez |
| Role | Chief Executive Officer |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 2000000 |
| Date | 9 Dec |
| Name | Aminov Erez |
| Role | Chief Executive Officer |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 500000 |
| Date | Name | Role | Transaction | Type | Shares |
|---|---|---|---|---|---|
| 9 Dec | Whalen Matthew Pratt | Director | Acquired | A-Award | 25000 |
| 9 Dec | MacPherson Edward Clouston | Director | Acquired | A-Award | 25000 |
| 9 Dec | Yanez Michelle | Chief Financial Officer | Acquired | A-Award | 150000 |
| 9 Dec | Aminov Erez | Chief Executive Officer | Acquired | A-Award | 2000000 |
| 9 Dec | Aminov Erez | Chief Executive Officer | Acquired | A-Award | 500000 |